Department of Medicine, The Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, New York, NY, USA.
Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101661. doi: 10.1016/j.beem.2022.101661. Epub 2022 Apr 11.
Hashimoto's thyroiditis (HT) and Graves' disease (GD) are prevalent autoimmune disorders, representing opposite ends of the clinical spectrum of autoimmune thyroid diseases (AITD). The pathogenesis involves a complex interplay between environment and genes. Specific susceptibility genes have been discovered that predispose to AITD, including thyroid-specific and immune-regulatory genes. Growing evidence has revealed that genetic and epigenetic variants can alter autoantigen presentation during the development of immune tolerance, can enhance self-peptide binding to MHC (major histocompatibility complex), and can amplify stimulation of T- and B-cells. These gene-driven mechanistic discoveries lay the groundwork for novel treatment targets. This review summarizes recent advances in our understanding of key AITD susceptibility genes (Tg, TSHR, HLA-DR3, and CD40) and their translational therapeutic potential.
桥本甲状腺炎(HT)和格雷夫斯病(GD)是常见的自身免疫性疾病,代表了自身免疫性甲状腺疾病(AITD)临床谱的两个极端。其发病机制涉及环境和基因之间的复杂相互作用。已经发现了特定的易感基因,这些基因易导致 AITD,包括甲状腺特异性和免疫调节基因。越来越多的证据表明,遗传和表观遗传变异可以改变免疫耐受过程中自身抗原的呈递方式,可以增强自身肽与 MHC(主要组织相容性复合体)的结合,并可以放大 T 细胞和 B 细胞的刺激作用。这些由基因驱动的机制发现为新型治疗靶点奠定了基础。本综述总结了我们对关键 AITD 易感基因(Tg、TSHR、HLA-DR3 和 CD40)及其潜在转化治疗的最新认识。